TY  - JOUR
TI  - CYP 2D6*4 polymorphism and interindividual response variation to metoprolol in stage 1 hypertensive patients: no association in a rural Indian population?
AB  - Background/aim: Genetic polymorphism of CYP2D6 shows diverse pharmacokinetic and pharmacodynamic variation. Terefore, thepresent work was designed to study the variation in therapeutic responses to metoprolol (MP) in stage 1 hypertensive patients and alsoaims to verify the association of CYP2D6*4 polymorphism and response variation in an Indian population for the frst time.Materials and methods: Clinically, a total of 119 hypertensive patients and 116 healthy individuals as controls were included. Patientswere treated with MP extended release 25 mg tablets once daily for 2 weeks. Reduction in systolic blood pressure, diastolic bloodpressure, and pulse rate were recorded before and afer the treatment. For genotyping, genotypes of 89 hypertensive patients and 71healthy controls were investigated for CYP2D6*4 polymorphism.Results: Based on reduction in systolic blood pressure, 26% of the patients did not respond to the MP treatment. Of the patients thatresponded, 28% responded very slowly, 35% (19 males, 23 females) responded moderately, and 12% (8 males, 6 females) showed agood response to MP. For genotype analysis, we pooled 89 hypertensive patients and 71 controls. No association was found betweenCYP2D6*4 polymorphism and MP response.Conclusion: We found no relationship between MP response and CYP2D6*4 genotype in an Indian population in our study.
AU  - JESTIN, Chelliah
AU  - AYYAPPADHAS, Rajagopal
AU  - DHANALEKSHMI, Unnikrishnan
PY  - 2015
JO  - Turkish Journal of Medical Sciences
VL  - 45
IS  - 2
SN  - 1300-0144
SP  - 352
EP  - 357
DB  - TRDizin
UR  - http://search/yayin/detay/171010
ER  -